Article
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.
BMC cancer - 19 May 2014
Kjersem Janne B, Skovlund Eva, Ikdahl Tone, Guren Tormod, Kersten Christian, Dalsgaard Astrid M, Yilmaz Mette K, Fokstuen Tone, Tveit Kjell M, Kure Elin H
Abstract excerpt
BACKGROUND: Polymorphisms of genes encoding the Fcy receptors (Fc fragment of IgG receptor 2A (FCGR2A) and 3A (FCGR3A)), which influence their affinity for the Fc fragment, have been linked to the pharmacodynamics of monoclonal antibodies. Most studies have been limited by small samples sizes and have reported inconsistent associations between the FCGR2A and the FCGR3A polymorphisms and clinical outcome in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.